Download

SAN DIEGO & RICHMOND, Va. & LJUBLJANA, Slovenia, & SYDNEY--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (OTCQB:APHBD), a global leader in
developing bacteriophage-based antibacterial therapies to treat drug
resistant infections, today announced that its shares of common stock
have been approved for listing on the NYSE MKT, subject to continued
satisfaction of listing requirements. The company anticipates its common
stock will begin trading on the NYSE MKT under the ticker APHB on August
21, 2015.

“We welcome AmpliPhi Biosciences to the NYSE MKT family of listed
companies and look forward to a long term partnership,” said Garvis
Toler, Global Head of Capital Markets, New York Stock Exchange.
“AmpliPhi is joining other well-known biotech companies taking advantage
of the NYSE’s innovative, leading market model for listing and trading
their shares.”

“The NYSE MKT listing represents a key milestone for AmpliPhi on our
mission to develop novel bacteriophage-based treatments to combat the
growing global threat posed by antibiotic-resistant bacteria, and extend
our leadership position in this competitive space,” said M. Scott Salka,
CEO of AmpliPhi. “We expect that trading our shares on the NYSE will
directly benefit our shareholders both by improving the liquidity of
their investment and enhancing our corporate profile amongst potential
investors and prospective partners.”

About AmpliPhi Biosciences

AmpliPhi Biosciences Corporation (OTCQB:APHBD) is a biotechnology
company focused on the development and commercialization of novel
bacteriophage-based antibacterial therapeutics. The Company's product
development programs target infections that are often resistant to
existing antibiotic treatments. AmpliPhi is collaborating with a number
of leading organizations, including Intrexon Corporation (NYSE:XON), the
U.S. Army, The Royal Brompton Clinic in London and The University of
Leicester, UK to rapidly advance bacteriophage-based therapies.

Bacteriophage are naturally occurring viruses that are highly specific
for the bacterial hosts they infect. They can rapidly kill their host,
amplifying themselves in the process. Bacteriophage are unaffected by
antibiotic resistance and are able to disrupt bacterial biofilms. Such
biofilms are a major line of defense for bacteria, contributing to
antibiotic resistance. Bacteriophage are able to penetrate biofilms and
replicate locally to high levels, to produce strong local therapeutic
effects.

Forward Looking Statements

Statements in this press release about AmpliPhi’s NYSE MKT listing,
trading liquidity of AmpliPhi stock, the potential use of bacteriophages
to treat bacterial infections, including infections in biofilms and
infections that do not respond to antibiotics, and the development of
bacteriophage-based therapies are forward looking statements subject to
risks and uncertainties, including without limitation the risk that the
Company may not be able to raise additional capital on acceptable terms,
if at all, that the Company will not be able to successfully manufacture
sufficient quantities of products to conduct clinical trials or
commercialize products in a timely manner or at all, that AmpliPhi may
not commence clinical trials or complete IND-enabling studies as
expected, that the Company’s clinical trials will not be successful,
that further development of the Company's products will require
extensive and expensive nonclinical and clinical testing, may not be
safe or efficacious, and may not be approved for marketing by the United
States Food and Drug Administration or any foreign regulatory agency.
For a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to AmpliPhi's
business in general, see AmpliPhi's Annual Report on Form 10-K for the
fiscal year ended December 31, 2014, as amended, filed with the
Securities and Exchange Commission (SEC) on April 15, 2015.